Id: acc3647
Group: 1sens
Protein: pRb
Gene Symbol: RB1
Protein Id: P06400
Protein Name: RB_HUMAN
PTM: phosphorylation
Site: Ser249
Site Sequence: KTAVIPINGSPRTPRRGQNRS
Disease Category: Cancer
Disease: Leukemia
Disease Subtype: Myeloid Leukemia
Disease Cellline: MV4-11
Disease Info:
Drug: Transforming growth factor beta
Drug Info: "Transforming growth factor beta is a cytokine that plays a crucial role in various cellular processes such as cell growth, differentiation, and apoptosis."
Effect: no effect
Effect Info: Transforming growth factor beta dephosphorylates pRB in tumor cells.
Note: no effect
Score: 2.0
Pubmed(PMID): 11027571
Sentence Index:
Sentence:

Sequence & Structure:

MPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTALCQKLKIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTELQKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKKYDVLFALFSKLERTCELIYLTQPSSSISTEINSALVLKVSWITFLLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYKTAVIPINGSPRTPRRGQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFMNSLGLVTSNGLPEVENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKSNLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASDQPSENLISYFNNCTVNPKESILKRVKDIGYIFKEKFAKAVGQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFSKLLNDNIFHMSLLACALEVVMATYSRSTSQNLDSGTDLSFPWILNVLNLKAFDFYKVIESFIKAEGNLTREMIKHLERCEHRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNLPLQNNHTAADMYLSPVRSPKKKGSTTRVNSTANAETQATSAFQTQKPLKSTSLSLFYKKVYRLAYLRLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKVKNIDLKFKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSVFMQRLKTNILQYASTRPPTLSPIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFGTSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQKLAEMTSTRTRMQKQKMNDSMDTSNKEEK

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
RB1-Ser249
Cancer Intensity
BRCA 0.68
COAD -0.657
HGSC 2.327
ccRCC 0.04
GBM 0
HNSC -0.544
LUAD -0.158
LUSC -1.828
non_ccRCC 0.079
PDAC -0.068
UCEC 0.13

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 249 U Breast cancer/tumor/carcinoma Phosphorylation 17599043

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM
Protein Gene PTM Position Modified sequence Cell Drug pEC50 Regulation Experiment
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A549 Dasatinib 6.3812 -
P06400 RB1 P Ser249;Thr252 TAVIPINGS(ph)PRT(ph)PR A431 Gefitinib 8.8586 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A431 Gefitinib 6.0858 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A431 Gefitinib 9.8958 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A549 AZD8055 8.7347 -
P06400 RB1 P Ser249;Thr252 TAVIPINGS(ph)PRT(ph)PR A549 Dactolisib 6.1766 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PRTPR A549 Dasatinib 8.8306 -
P06400 RB1 P Ser249;Thr252 TAVIPINGS(ph)PRT(ph)PR A549 Dasatinib 8.7717 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A549 Dasatinib 6.7636 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A431 Gefitinib 7.2577 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A549 Nintedanib 3.7662 -
P06400 RB1 P Ser249;Thr252 TAVIPINGS(ph)PRT(ph)PR A549 PD325901 10.6071 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A549 PD325901 7.315 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A549 Refametinib 10.9916 -
P06400 RB1 P Ser249;Thr252 TAVIPINGS(ph)PRT(ph)PR A549 Staursporin 7.642 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A549 Staursporin 6.279 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A549 Tideglusib 7.2696 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR K562 Paclitaxel 9.0409 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A431 Dasatinib 5.4421 -
P06400 RB1 P Ser249;Thr252 TAVIPINGS(ph)PRT(ph)PR A431 Afatinib 7.2253 -
P06400 RB1 P Ser249;Thr252 TAVIPINGS(ph)PRT(ph)PR A431 Afatinib 8.5301 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A431 Afatinib 7.3297 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A431 Afatinib 8.7462 -
P06400 RB1 P Ser249;Thr252 TAVIPINGS(ph)PRT(ph)PR A431 Afatinib 7.1355 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A431 Afatinib 8.3241 -
P06400 RB1 P Ser249;Thr252 TAVIPINGS(ph)PRT(ph)PR A431 Afatinib 7.7579 -
P06400 RB1 P Ser249;Thr252 TAVIPINGS(ph)PRT(ph)PR A431 Dasatinib 6.2497 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A431 Afatinib 7.8106 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A431 Dasatinib 13.3845 -
P06400 RB1 P Ser249;Thr252 TAVIPINGS(ph)PRT(ph)PR A431 Dasatinib 7.148 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A431 Dasatinib 7.0424 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A431 Dasatinib 8.2985 -
P06400 RB1 P Ser249;Thr252 TAVIPINGS(ph)PRT(ph)PR A431 Dasatinib 5.1816 -
P06400 RB1 P Ser249;Thr252 TAVIPINGS(ph)PRT(ph)PR A431 Gefitinib 7.9731 -
P06400 RB1 P Ser249 TAVIPINGS(ph)PR A431 Gefitinib 2 -
P06400 RB1 P Ser249;Thr252 TAVIPINGS(ph)PRT(ph)PR A431 Gefitinib 8.2497 -

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links: